Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Introduction: Liver cirrhosis is a growing global healthcare challenge. Cirrhosis is characterised by severe liver fibrosis, organ dysfunction and complications related to portal hypertension. There are no licensed antifibrotic or proregenerative medicines and liver transplantation is a scarce resource. Hepatic macrophages can promote both liver fibrogenesis and fibrosis regression. The safety and feasibility of peripheral infusion of ex vivo matured autologous monocyte-derived macrophages in patients with compensated cirrhosis has been demonstrated. Methods and analysis: The efficacy of autologous macrophage therapy, compared with standard medical care, will be investigated in a cohort of adult patients with compensated cirrhosis in a multicentre, open-label, parallel-group, phase 2, randomised controlled trial. The primary outcome is the change in Model for End-Stage Liver Disease score at 90 days. The trial will provide the first high-quality examination of the efficacy of autologous macrophage therapy in improving liver function, non-invasive fibrosis markers and other clinical outcomes in patients with compensated cirrhosis. Ethics and dissemination: The trial will be conducted according to the ethical principles of the Declaration of Helsinki 2013 and has been approved by Scotland A Research Ethics Committee (reference 15/SS/0121), National Health Service Lothian Research and Development department and the Medicine and Health Care Regulatory Agency-UK. Final results will be presented in peer-reviewed journals and at relevant conferences. Trial registration numbers: ISRCTN10368050 and EudraCT; reference 2015-000963-15
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Sepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., Poustchi, H., Tsoi, D., Colombara, D. V., Abdoli, A., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30349-8 · Cited by 1,714
The model for end-stage liver disease (MELD)
Kamath, P. S., & Kim, R. W. (2007) · Hepatology · doi:10.1002/hep.21563 · Cited by 1,674
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001
Self-citationThomas, J. A., Pope, C., Wojtacha, D., Robson, A. J., Gordon-Walker, T. T., Hartland, S., Ramachandran, P., Van Deemter, M., Hume, D. A., Iredale, J. P., et al. (2011) · Hepatology · doi:10.1002/hep.24315 · Cited by 346
Self-citationPavlides, M., Banerjee, R., Sellwood, J., Kelly, C. J., Robson, M. D., Booth, J. C., Collier, J., Neubauer, S., & Barnes, E. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.009 · Cited by 212
Alternatively activated macrophages promote resolution of necrosis following acute liver injury
Starkey Lewis, P., Campana, L., Aleksieva, N., Cartwright, J. A., Mackinnon, A., O'Duibhir, E., Kendall, T., Vermeren, M., Thomson, A., Gadd, V., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.031 · Cited by 209
Self-citationSafety profile of autologous macrophage therapy for liver cirrhosis
Moroni, F., Dwyer, B. J., Graham, C., Pass, C., Bailey, L., Ritchie, L., Mitchell, D., Glover, A., Laurie, A., Doig, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0599-8 · Cited by 202
Self-citationFatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection
Kallman, J., O’Neil, M. M., Larive, B., Boparai, N., Calabrese, L., & Younossi, Z. M. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9708-x · Cited by 181
Bird, T. G., Lu, W.-Y., Boulter, L., Gordon-Keylock, S., Ridgway, R. A., Williams, M. J., Taube, J., Thomas, J. A., Wojtacha, D., Gambardella, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302168110 · Cited by 166
Self-citation
Cited by
Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial
Brennan, P. N., MacMillan, M., Manship, T., Moroni, F., Glover, A., Troland, D., MacPherson, I., Graham, C., Aird, R., Semple, S. I. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03406-8 · Cited by 66
Self-citationImmunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Guillot, A., & Tacke, F. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000491 · Cited by 45
Protozoan‐Derived Cytokine‐Transgenic Macrophages Reverse Hepatic Fibrosis
Chen, Y., Wang, J., Zhou, N., Fang, Q., Cai, H., Du, Z., An, R., Liu, D., Chen, X., Wang, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202308750 · Cited by 12
Lei, M., & Chen, G. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.05.011 · Cited by 12
Metadata
- Authors
- Brennan, P. N., MacMillan, M., Manship, T., Moroni, F., Glover, A., Graham, C., Semple, S., Morris, D. M., Fraser, A. R., Pass, C., McGowan, N. W. A., Turner, M. L., Lachlan, N., Dillon, J. F., Campbell, J. D. M., Fallowfield, J. A., & Forbes, S. J.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2021-11
- Volume
- 11
- Issue
- 11
- Pages
- e053190
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W3212174053
- Cited by
- 41
- References
- 12
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH). https://app.cochat.ai/papers/10.1136/bmjopen-2021-053190
- The paper
- Brennan, P. N., MacMillan, M., Manship, T., Moroni, F., Glover, A., Graham, C., Semple, S., Morris, D. M., Fraser, A. R., Pass, C., McGowan, N. W. A., Turner, M. L., Lachlan, N., Dillon, J. F., Campbell, J. D. M., Fallowfield, J. A., & Forbes, S. J. (2021). Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH). BMJ Open. https://doi.org/10.1136/bmjopen-2021-053190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.